Completed PHASE3 INTERVENTIONAL NCT00309036

Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis

A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Cocktail of Recombinant Derivatives of Major Allergens of Timothy Grass (Phleum Pratense).

Sponsor: Allergopharma GmbH & Co. KG

Conditions Allergy

Interventions Recombinant grass pollen

Updated 5 times since 2017 Last updated: Mar 8, 2013 Started: Jan 31, 2004 Primary completion: Sep 30, 2006 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Allergy and is currently completed. Allergopharma GmbH & Co. KG leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergopharma GmbH & Co. KG

Data source: Allergopharma GmbH & Co. KG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Reinbek, Germany